Commentary|Articles|July 29, 2026
The Great 340B Debate: What Pharmacists Need to Know
Author(s)Brian Nowosielski
Tom Kraus, JD, of ASHP, and Shawn Gremminger, MPP, of the National Alliance of Healthcare Purchaser Coalitions, face off on the 340B Drug Pricing Program.
Advertisement
Advertisement
The 340B Drug Pricing Program has quietly grown into one of the largest, most contested financial arrangements in the American health care ecosystem. For pharmacists, they sit closer to its mechanics than almost any other industry stakeholder, making this group of providers key in systematic conversations regarding the program’s future.
Advertisement
Advertisement
